Transcription dysfunction in disease

PhD Enquiry - Transcription Dysfunction in Disease

Queen's University Belfast

School of Medicine, Dentistry and Biomedical Sciences

Location
Belfast, United Kingdom
Funding
See university guidance
Application deadline
See university guidance

About the project

The Functional Genomics Group focusses on the use of cutting-edge genomics technologies to investigate transcription factor function and de-regulation in cancer with a particular interest in the p53 family.

We believe that a better understanding of the genome-wide targets, mechanism of action and consequences of de-regulation of key transcription factors; will allow us to identify cancer specific dependencies, that represent “Achilles heels”, exploitable with novel treatment strategies to improve patient outcomes.

  • Dr Simon McDade: School of Medicine, Dentistry and Biomedical Sciences

Contact info

  • View Academic Profile
  • askmhls@qub.ac.uk
  • +44 (0)28 9097 2183

Research Interests

Open to PhD applications in the field of

Make a PhD enquiry

  • Transcription dysfunction in disease
  • Functional genomics and integrative bioinformatics
  • Identification of novel genomically informed treatment strategies

Current Research Opportunities

  • Using epigenetic modifiers in combination with 5-FU based chemotherapy to elicit tumour specific immune responses and immunogenic cell death in colorectal cancer.
  • Novel approaches to uncovering effects of anti-cancer agents targeting epigenetic modifiers.
  • Integrative Functional Genomics of Chemotherapy Response and Resistance in Colorectal Cancer
  • Integrative Genomic Mapping of Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
  • Integrative Genomic Analysis of Androgen Deprivation Therapy Resistance in Prostate Cancer
  • Using epigenetic modifiers in combination with 5-FU based chemotherapy to elicit tumour specific immune responses and immunogenic cell death in colorectal cancer.
  • Novel approaches to uncovering effects of anti-cancer agents targeting epigenetic modifiers.

Public outreach & key achievements

  • Academic Lead FMHLS Genomics Core Technology Unit
  • Co-Investigator on CRUK Colorectal Cancer Program Grant funded by Bobby Moore Foundation
  • Co-Investigator PCUK-Movember QUB-Manchester Centre of Excellence
  • Pre-Clinical Lead CRUK New Agents Committee sponsored first-in-human trial of CDC7 inhibitor to exploit p53 deficiency

Discover More

  • Faculty of Medicine, Health and Life Sciences
  • School of Medicine, Dentistry and Biomedical Sciences
  • The Patrick G Johnston Centre for Cancer Research
  • Genomics
  • Gastro-Intestinal Focus Group

Research areas

Transcription dysfunction in diseaseBioinformaticsTranscriptiongenomicsGenomics

Related PhD opportunities